Revelation Biosciences Files Adaptive Phase 2/3 Plan, Bolsters $10.7M Cash Runway
Revelation Biosciences ended 2025 with $10.7 million in cash, up from $6.5 million, and expects funding into Q1 2027. It reported a 2025 net loss of $8.9 million and secured FDA agreement on an adaptive Phase 2/3 study for its Gemini therapy in acute kidney injury.
1. Corporate Highlights
Revelation Biosciences reported positive PRIME study results in late-stage chronic kidney disease and reached agreement with the FDA on a single adaptive Phase 2/3 trial for Gemini in acute kidney injury. The company also received $6.7 million from a warrant inducement in January 2026 and plans to present additional Gemini data at a critical care nephrology conference.
2. Financial Results
For the year ended December 31, 2025, the company recorded a net loss of $8.9 million, or $23.95 per share, compared to a $15.0 million loss in 2024. Net cash used in operations fell to $8.3 million from $18.3 million the prior year, reflecting lower operating expenses and financing activities.
3. Outlook and Runway
Revelation held $10.7 million in cash and equivalents at year-end, up from $6.5 million a year earlier, and expects its current cash position to fund operations into the first quarter of 2027. The company will focus on advancing its Gemini program through the agreed adaptive Phase 2/3 study and upcoming clinical presentations.